Monday - April 14, 2025

LOGIN  |  REGISTER
Viking Therapeutics
Compass Therapeutics

CareCloud's Bill Korn, Chief Strategy Officer, and Joseph DosSantos, Chief Financial Officer, to Host Investor Meetings at Upcoming Conferences

May 09, 2023 | Last Trade: US$1.34 0.15 12.61

SOMERSET, N.J., May 09, 2023 (GLOBE NEWSWIRE) -- CareCloud, Inc. (Nasdaq: CCLD, CCLDP, CCLDO), a leader in healthcare technology solutions for medical practices and health systems nationwide, announced today that Bill Korn, chief strategy officer, and Joseph DosSantos, chief financial officer, will be available to meet with investors and discuss CareCloud's strategy and financial performance at several upcoming healthcare conferences.

To arrange a meeting with Bill and Joe, investors can contact Bridget Forde at CareCloudIR@westwicke.com.

About CareCloud

CareCloud (Nasdaq: CCLD, CCLDP, CCLDO) brings disciplined innovation to the business of healthcare. Our suite of technology-enabled solutions helps clients increase financial and operational performance, streamline clinical workflows and improve the patient experience. More than 40,000 providers count on CareCloud to help them improve patient care while reducing administrative burdens and operating costs. Learn more about our products and services, including revenue cycle management (RCM), practice management (PM), electronic health records (EHR), business intelligence, patient experience management (PXM) and digital health, at www.carecloud.com.

Follow CareCloud on LinkedInTwitter and Facebook.

SOURCE CareCloud

Company Contact:
Bill Korn
Chief Strategy Officer
CareCloud
bkorn@carecloud.com

Investor Contact:
Asher Dewhurst
ICR Westwicke
CareCloudIR@westwicke.com

Media Inquiries:
Alexis Feinberg
ICR Westwicke
CareCloudPR@westwicke.com

C4 Therapeutics

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page